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Abstract
Objective To test the effectiveness of telemonitoring integrated into
existing clinical services such that intervention and control groups have
access to the same clinical care.
Design Researcher blind, multicentre, randomised controlled trial.
Setting UK primary care (Lothian, Scotland).
Participants Adults with at least one admission for chronic obstructive
pulmonary disease (COPD) in the year before randomisation. We
excluded people who had other significant lung disease, who were unable
to provide informed consent or complete the study, or who had other
significant social or clinical problems.
Interventions Participants were recruited between 21 May 2009 and
28 March 2011, and centrally randomised to receive telemonitoring or
conventional self monitoring. Using a touch screen, telemonitoring
participants recorded a daily questionnaire about symptoms and
treatment use, andmonitored oxygen saturation using linked instruments.
Algorithms, based on the symptom score, generated alerts if readings
were omitted or breached thresholds. Both groups received similar care
from existing clinical services.
Main outcome measures The primary outcome was time to hospital
admission due to COPD exacerbation up to one year after randomisation.
Other outcomes included number and duration of admissions, and
validated questionnaire assessments of health related quality of life
(using St George’s respiratory questionnaire (SGRQ)), anxiety or
depression (or both), self efficacy, knowledge, and adherence to
treatment. Analysis was intention to treat.
Results Of 256 patients completing the study, 128 patients were
randomised to telemonitoring and 128 to usual care; baseline
characteristics of each group were similar. The number of days to
admission did not differ significantly between groups (adjusted hazard
ratio 0.98, 95% confidence interval 0.66 to 1.44). Over one year, the
mean number of COPD admissions was similar in both groups
(telemonitoring 1.2 admissions per person (standard deviation 1.9) v
control 1.1 (1.6); P=0.59). Mean duration of COPD admissions over one
year was also similar between groups (9.5 days per person (standard
deviation 19.1) v 8.8 days (15.9); P=0.88). The intervention had no
significant effect on SGRQ scores between groups (68.2 (standard
deviation 16.3) v 67.3 (17.3); adjusted mean difference 1.39 (95%
confidence interval −1.57 to 4.35)), or on other questionnaire outcomes.
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Conclusions In participants with a history of admission for exacerbations
of COPD, telemonitoring was not effective in postponing admissions
and did not improve quality of life. The positive effect of telemonitoring
seen in previous trials could be due to enhancement of the underpinning
clinical service rather than the telemonitoring communication.
Trial registration ISRCTN96634935.
Funding: The trial was funded by an NHS applied research programme
grant from the Chief Scientist Office of the Scottish government
(ARPG/07/03). The funder had no role in study design and the collection,
analysis, and interpretation of data and the writing of the article and the
decision to submit it for publication. NHS Lothian supported the
telemonitoring service and the clinical services.
Introduction
Potentially affecting one in four adults by the age of 80 years,1
chronic obstructive pulmonary disease (COPD) is already a
leading cause of death and disability in high, middle, and low
income countries.2 3 Telemonitoring has attracted interest as a
potential solution to the global challenge of providing care for
ageing populations living with long term conditions such as
COPD,4 leading to its enthusiastic promotion by policymakers.5 6
The recent UKWhole SystemsDemonstrator (WSD) evaluation
analysed a cohort of patients with conditions including COPD,
diabetes, and heart failure.7 The study’s findings lend some
support to the assertion that a service redesign that included
telemonitoring can reduce admissions and mortality in people
with long term conditions, although not cost effectively.8
Despite calls for robust effectiveness trials of telemonitoring in
COPD,9 five systematic reviews have reported inconclusive
results.10-14 Patients’ attitudes and receptiveness towards this
approach are “promising,”13 but the evidence is insufficient to
draw firm conclusions about clinical effectiveness10 12 13 or cost
effectiveness.13 The heterogeneity of interventions that use
telemonitoring contributes to the difficulty in interpreting
outcomes—ranging from “simple” telephone follow-up to daily
telemonitoring of physiological or symptom scores or to more
complex telemonitoring interventions with greatly enhanced
clinical support.10 14 This heterogeneity has led to calls for further
research to clarify the specific role of telemonitoring (as opposed
to the additional clinical services created to support it) in
managing people with COPD.10
To inform the ongoing debate, we designed a study in which
telemonitoring was integrated into existing clinical services,
such that monitoring was provided by clinical teamswho already
had (or were about to assume) clinical responsibility for the
patients. Both intervention and control groups had access to the
same clinical care: the only difference between the groups was
the use of telemonitoring.15
Methods
We conducted a 12 month, researcher blinded, randomised
controlled trial in primary care in the United Kingdom, which
recruited participants between 21May 2009 and 28March 2011.
A detailed protocol has been published.15 We did not make any
substantive changes to the trial procedures, but after pilot work,16
wemade someminor procedural changes to enhance recruitment
and to streamline the collection of data from participants’
healthcare records. A detailed statistical analysis plan was
submitted to the trial sponsor before completion of data
collection.
Participants
We recruited adults registered with Lothian general practices
who had been admitted to hospital with an exacerbation of
COPD in the previous year and who were thus at risk of future
admissions.17 Our eligibility criteria were as inclusive as
possible, including patients of all ages and with a range of
comorbidities.18 Thus, we only excluded people with other
significant lung disease; who were unable to provide informed
consent, use the technology, or complete the questionnaires; or,
on the advice of their general practitioner (GP), for other
significant social or clinical problems.
Participant recruitment
We used three strategies to identify potentially eligible
participants. Community respiratory and nursing teams screened
their caseloads. Respiratory consultants identified and contacted
potentially eligible patents from hospital admission data from
the Information Services Division (www.isdscotland.org/).
Finally, supported by the Scottish Primary Care Research
Network, 96 primary care practices searched for patients in their
databases. With GP agreement, the responsible clinician sent
trial information to all eligible patients inviting them to express
interest in participating in the trial.
Potentially interested participants were invited, with one
reminder, to a baseline assessment with a research nurse in their
home at least six weeks after the most recent exacerbation
(whether an admission or managed at home). The research nurse
provided further information about the trial and obtained
consent. Diagnosis of COPD was confirmed by the presence of
chronic airflow limitation on spirometry normally performed
at the baseline assessment by the research nurse trained in
spirometry. COPD was confirmed if the post-bronchodilator
forced expiratory volume in one second (FEV1) divided by the
forced vital capacity was less than 0.7.19Recordings undertaken
by a specialist respiratory service within the previous three
months were accepted if spirometry at the baseline assessment
was not possible or declined. All consenting participants meeting
the eligibility criteria were enrolled into the trial.
Primary outcome measure
The primary aim of the intervention was to reduce the frequency
of admissions. Therefore, our primary outcome measure was
the time to first hospital admission with a primary diagnosis of
an exacerbation of COPD up to one calendar year after
randomisation. We defined an exacerbation as a sustained
worsening of the participant’s symptoms from their usual stable
state that was beyond normal day-to-day variations, was acute
in onset, and necessitated a change in treatment.20 An
exacerbation was considered the “primary diagnosis” if the
presenting symptoms were consistent with and the participant
was treated for an acute exacerbation of COPD, and if no other
disease was treated as a priority.
Secondary outcome measures
Full details of the secondary outcome measures are in the
published protocol.15Briefly, wemeasured the difference of the
items listed in the box at one year after randomisation.
Baseline assessment
Weundertook a baseline assessment comprising current smoking
status, UKMedical Research Council dyspnoea score,26 history
of COPD, presence of comorbidity, and baseline questionnaires.
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Secondary outcome measures
Exacerbations, admissions, and deaths
Time until first hospital admission with an exacerbation of COPD or all cause death
Number and duration of hospital admissions with an exacerbation of COPD; number and duration of admissions in which COPD was a
factor (for example, listed as a significant comorbidity, or as an overnight admission for minor surgery that might otherwise have been
a day case)
Number and duration of admissions for any cause
Number of deaths at one year
Number of exacerbations self reported by participants on quarterly questionnaires. This included all exacerbations treated with steroids
or antibiotics, whether commenced by the patient, primary care, or secondary care including during an admission.
Questionnaire assessment of health related quality of life, anxiety and depression, participant knowledge, and self efficacy
and adherence with treatment
St George’s respiratory questionnaire (SGRQ)21 (both mean difference and proportion of participants with scores improving by the
minimum clinically important difference (defined as four units))
Hospital anxiety and depression scale (HADS)22
Self efficacy for managing chronic disease 6 item scale (SECD6)23
Lung information needs questionnaire (LINQ)24
Medication adherence report scale (MARS).25
Healthcare resource use
Number and duration of contacts (telephone, clinic visits, or home visits) with community services
Randomisation and protection against bias
Existing clinical care varied in intensity and organisation
throughout the four regions of Lothian. Therefore, consenting
participants were stratified by the clinical service providing
their existing COPD care (see below for clinical care
arrangements) and centrally randomised to either control or
intervention with a 1:1 allocation using randomised blocks of
two or four. This process was managed by the telephone
randomisation service of the Edinburgh Clinical Trials Unit,
ensuring concealment until the treatment was assigned. The
research nurse phoned the randomisation service, informed the
participant of the allocation, and referred intervention
participants for installation of the telemonitoring equipment.
The research nurse responsible for follow-up assessments was
different to the nurse who performed randomisation, and data
entry was undertaken by trial administrators blinded to
allocation. All primary outcome assessors were blind to the
allocation.
Trial intervention: telemonitoring
Figure 1⇓ illustrates the model of telemonitoring. The
telemonitoring equipment and secure broadband link was
installed in the homes of intervention participants. The clinical
team responsible for their care then visited the participant at
home to explain how to use the technology and provide self
management education. Participants had access to technological
advice and support throughout the trial.
Using the touch screen telemonitoring equipment, the participant
recorded and transmitted a daily questionnaire about symptoms
and use of treatment (web appendix 1), and monitored oxygen
saturation using linked validated instruments. The symptom
score was based on validated diary cards,28 and the patient was
asked to assess if their dyspnoea, sputum purulence and volume,
cough, wheeze had increased or if they had developed an upper
respiratory tract infection or had a fever. The responses were
weighted as described in the validation studies: positive answers
to cardinal symptoms of an exacerbation of COPD scored 2,
the remaining questions scored 1.28
This information was sent by a secure internet connection to a
password protected server at the UK’s health service, which
was accessible to the supporting clinical team. The supporting
clinical team (a specialist respiratory team in Edinburgh, a nurse
specialist in long term conditions in Midlothian, or a trained
call handler working with general practices for patients living
in East or West Lothian) monitored the daily online data.
Algorithms, based on the symptom score, alerted the clinical
monitoring team if daily readings had not been submitted or if
a score of 4 or 5 had been recorded (web appendix 2).15
The action taken was the responsibility of the monitoring
clinician who normally knew the patient and was able to
interpret the monitoring data in the light of the patient’s history.29
Typically, this involved contacting the patient by telephone
(although the system could support a video link) and undertaking
a further clinical assessment to enable a decision about further
management (for example, commencing rescue treatment, a
home visit, immediate admission, or reviewing the following
day). Although a video link was available, poor reception meant
that it was only used on two occasions. Pulse oximetry data
were available to inform the clinical assessment, and clinicians
were able to define an “oxygen saturation” alert on an individual
patient basis.
Control group
To ensure that our trial specifically tested the effect of the
telemonitoring technology, intervention and control groups were
provided with the same clinical care (including self management
advice) according to the region in which they lived (see below).
The only difference between the intervention and control groups
was the provision of the telemonitoring service.
Clinical care in both groups
Clinical care in both groups was in accordance with the Lothian
protocols, which were based on national and international
guideline recommendations.19 20 Education on self management
of exacerbations was provided for all participants, reinforced
by a copy of the British Lung Foundation’s booklet about living
with COPD,30 which includes a written management plan, and
an emergency supply of antibiotics and steroids were made
available.
Different service models operated in the four regions of Lothian.
A dedicated respiratory physiotherapy service was available
seven days a week for participants in the city of Edinburgh.
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Nurse specialists in long term conditions provided a weekday
service for participants in the mixed urban and rural population
of Midlothian. In East and West Lothian, care was provided by
the participants’ registered GP: telemonitoring data were
monitored by a trained administrative assistant who referred
participants to their GP according to the algorithm used in our
pilot study (web appendix 2).16 Randomisation was stratified
by these different services to allow for the possibility that
outcomes might not be comparable in the different areas.
Data collection
Data on admissions were extracted from the hospital records at
the end of the trial. The number of admissions identified was
cross referenced with the admissions reported by the patients
to ensure that we captured events occurring away from the
patients’ usual hospital. The cause of the admission (and thus
whether the event counted as a primary outcome) was assessed
independently from the hospital discharge summary by HP and
BM with disagreements resolved by discussion (with WM
arbitrating, if necessary). Questionnaires were administered by
a research nurse at a home visit arranged within two weeks of
the calendar year during which the participant was in the trial.
Healthcare resource use was collected by questionnaire posted
to the participants three, six, and nine months (one reminder)
and by the research nurse at baseline and the 12 month
assessment. Healthcare resource use included consultations with
GPs and nurses, respiratory and nursing teams, out of hours
services, emergency services, telephone calls to the NHS 24
health information and self care advice service, and courses of
oral steroids and antibiotics. The respiratory physiotherapy
service in Edinburgh and the nurses in Midlothian maintained
detailed timesheets of all patient contacts. All data were entered
manually onto the trial database, with 10% checked for accuracy
by an external assessor.
Sample size calculations
We estimated that 125 participants in each arm would allow us
to detect a difference in the primary outcome of time to
admission from a median of 200 days in the control group to
300 days in the intervention group, with 80% power, using a
significance level of 5% (log rank test). This estimate was based
on data from the largest study of telemonitoring available at the
time (n=155), which showed an increase in the time to admission
from a median of about 200 days to 400 days.31 Because
effectiveness in that trial varied between centres, we opted for
a conservative estimate of effect size. To allow for 10%
withdrawal from follow-up and 7% of deaths occurring before
admission to hospital with COPD, we increased our target
recruitment to 150 per arm. We monitored withdrawals and
deaths before admission with an exacerbation of COPD, which
proved considerably lower than our estimates, enabling us to
stop recruitment at 128 participants in each group.
Data analysis
All participants who were randomised were followed up and
included in the analysis in their allocated treatment groups
regardless of the treatment actually received (intention to treat
analysis). Survival data were presented using Kaplan-Meier
curves,32 analysed using Cox proportional hazards models33
adjusting for potentially important confounders. These
confounders were service (stratification variable), age, sex,
severity (post-bronchodilator FEV1% predicted), current
smoking status, presence of comorbidity, SGRQ score, HADS
score, social class (based on postcode and the Scottish Index of
Multiple Deprivation), and number of previous admissions.
Binary outcomes were analysed using logistic regression and
continuous outcomes were analysed using generalised linear
models. However, for the majority of the analyses on number
and duration of hospital admissions, a Poisson distribution
function was used owing to the data being heavily skewed,
adjusting for the stratification variable and potential
confounders. Unadjusted analyses were also performed.Where
appropriate, adjustments weremade for baseline measurements
using analysis of covariance.
Because the primary outcome and majority of the secondary
outcomes were analysed using survival analysis, any missing
data were censored at the point when the data became missing.
Participants who died without having had an admission with a
primary diagnosis of COPDwere censored in the final analysis.
For other analyses, participants with missing data were omitted
as necessary.
Subgroup analyses
For the primary outcome, planned subgroup analyses were
performed based on age, sex severity, presence of any
comorbidity, and SGRQ and HAD scores, because these could
be hypothesised to affect the impact of the intervention.34
Subgroup analyses were performed by adding the interaction
between these factors and treatment into the survival analysis
model and by observing whether the change in the model log
likelihood was statistically significant. All analyses were agreed
a priori. We did not plan or undertake any interim analysis.
Results
Recruitment
Figure 2⇓ details the flow of participants through the trial. Of
422 patients identified by clinical services, the GP refused
permission to approach three patients for significant clinical or
social reasons, leaving 419 who were potentially eligible and
were sent an invitation letter by the clinical team. Of these, 314
patients expressed an interest in participating and 258 provided
informed consent. Two patients withdrew consent (for personal
reasons) before randomisation, so that 256 were randomised
equally between the two groups. Two participants withdrew
their consent during the course of the trial (one in each group).
Baseline characteristics
Demographic characteristics of participants, social deprivation,
markers of disease severity (including admissions in the previous
year), presence of comorbidities, smoking status, and baseline
questionnaire scores were similar in both groups. However,
slightly fewer patients in the intervention group than in the
control group had one or more comorbid conditions (61% v
71%; table 1⇓). The demographic profile of the participants
(mean age 69.4 (standard deviation 8.6) years; 45% male) was
similar to that of the population referred by their clinician as
potentially eligible and willing for their contact details to be
passed to the research team (69.8 (9.1) years; 43%).
Hospital admission with an exacerbation of
COPD
The median time to the first hospital admission with an
exacerbation of COPD was 362 days (interquartile range 131
to >365) in the telemonitoring group and 361 days (113 to >365;
fig 3⇓) in the control group. There was no significant difference
in the hazard ratio for admission in the telemonitoring group
compared with the control group (adjusted hazard ratio 0.98
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(95% confidence interval 0.66 to 1.44)). Similarly, there was
no significant difference in the number of admissions with an
exacerbation of COPD, or the total number of days spent in
hospital (table 2⇓). Unadjusted results (data not shown) were
similar to the adjusted analyses.
Four deaths occurred before admission to hospital with COPD
(one in the telemonitoring group) and were censored in the
primary analysis. Using a composite outcome of time to first
COPD admission or all cause death, the adjusted hazard ratio
for admission in the telemonitoring group was 0.87 (95%
confidence interval 0.61 to 1.26) compared with the control
group.
Self reported COPD exacerbations, all cause
admissions, and deaths
The telemonitoring group showed a non-significant increase in
the number of self reported exacerbations per patient during the
calendar year compared with controls (mean 15.0 (standard
deviation 12.7) v 12.8 (11.8); adjusted mean difference 2.29
(95% confidence interval −0.78 to 5.37)). A self reported
exacerbation was defined as a patient report of an episode of
taking antibiotics or steroids. The number and duration of
admissions for which an exacerbation was not the primary cause
were similar in both groups (table 2). The number of deaths did
not differ significantly between the telemonitoring and control
groups (16 v 21; adjusted odds ratio 0.66 (95% confidence
interval 0.29 to 1.48)).
Questionnaire responses
There was no significant difference between the groups in any
of the questionnaire scores, and no differences from baseline to
one year in either group. The intervention made no significant
difference to health related quality of life the telemonitoring
and control groups (mean SGRQ score at one year, 68.2
(standard deviation 16.3) v 67.3 (17.3); adjustedmean difference
1.39 (95% confidence interval −1.57 to 4.35)), anxiety or
depression, self efficacy, knowledge, or adherence to treatment
(table 3⇓). The proportion of participants whose SGRQ20 score
improved by more than four units (the minimum clinically
important difference) was 25% in the telemonitoring arm and
25% in the control group.
Installation of telemonitoring equipment,
training, and withdrawals
Table 4⇓ details the logistics of installing and training
participants to use the equipment and reasons for withdrawals.
The mean time from randomisation to commencing monitoring
was 79 days (standard deviation 48 days), with nearly three
quarters of the delay related to the installation of a dedicated
broadband line and setting up of the telemonitoring equipment.
Of 128 participants allocated to telemonitoring, 113 had the
equipment successfully installed and 109 completed training.
Eight participants withdrew from telemonitoring during the
trial, mostly because of changes in clinical circumstances.
Contacts with clinical monitoring teams
Table 5⇓ details the contacts with healthcare monitoring services
for the 189 patients under the care of the Edinburgh Community
Respiratory Team and the Midlothian nurses. Data for East and
West Lothian services were incomplete because care was
provided by a number of general practices and contacts were
not recorded consistently. The community teams dealt with
2441 telemonitoring alerts from the 97 telemonitored patients
under their care, 113 of which required home visits. This
represented an average of 25 contacts per patient over the year
of the trial—about one contact every two weeks, in addition to
the 510 telephone calls and 821 home visits to telemonitored
patients that were not directly associated with alerts. The 92
patients in the control group received fewer telephone calls and
home visits than those in the telemonitoring group (353 and
681, respectively).
Subgroup analyses
Figure 4⇓ shows the subgroup analyses. The only significant
result was that the intervention was less effective for participants
with mild or moderate COPD than for those with severe or very
severe COPD. Although this was an a priori analysis, severity
was one of seven subgroups tested and was based on a small
number of patients in the mild or moderate group; therefore, it
is subject to considerable uncertainty.
Discussion
In participants with a recent history of admission for
exacerbations of COPD, telemonitoring over one year did not
have a significant benefit on time to a hospital admission,
duration of admissions, or health related quality of life when
both intervention and control groups had access to the same
clinical care. Furthermore, telemonitoring was associated with
a large increase in the number of telephone consultations and
home visits, and a non-significant increase in participant
reported exacerbations. Telemonitoring thus did not represent
an effective use of NHS resources.
Strengths and limitations
Our researcher blinded pragmatic trial, which built on relevant
conceptual and systematic review work,10 15 reports clinical
effectiveness and workload implications of telemonitoring for
COPD.We obtained the primary outcome data from the clinical
records of all but two participants, and thus achieved our target
sample size. There was some attrition of questionnaire
completion, principally because of deaths during the trial year,
and because several participants felt it was too burdensome
given their state of health at the time.
The confidence intervals for our primary outcome were wide
(0.66 to 1.44) and we cannot be confident of ruling out a
clinically meaningful difference that was smaller than the one
we were powered to study. Our admission related secondary
outcomes, however, similarly showed no significant effect. Our
sample size was based on a study conducted a decade ago.31
However, in the intervening years, there has been a considerable
drive to reduce the number and duration of admissions
(including the development of community respiratory teams
who provided clinical care for the majority of our participants),
thus limiting the potential for further reduction.
We ensured that both groups had access to the same clinical
care, which in our UK setting was facilitated by the availability
of established community specialist respiratory teams, specialist
nurses for long term conditions, or primary care teams. The
clinical services into which the telemonitoring was integrated
varied between the four Lothian regions, which may have
influenced the effect of the intervention and the potential for
improvement; we therefore stratified randomisation by service
model. Most participants lived within 10 miles of secondary
care facilities: outcomes might have been different in rural areas
where telemonitoring might have had a greater effect on
enhancing access to care.
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Blinding of participants and treating clinicians was not possible,
but central randomisation ensured concealment and the primary
outcome was assessed by two clinicians unaware of allocation.
To achieve blinding of data collection, outcome data were
collected by a different member of the research team from the
nurse who had randomised the patients, but we acknowledge
that participants could have mentioned telemonitoring, or
equipment might have been visible during the home visit for
data collection, making it impossible to maintain blinding in all
cases.
Interpretation of findings
Our findings highlight the importance of defining the nature of
usual care delivered to a control group when evaluating a
complex intervention. Previous studies that have introduced an
enhanced clinical service to support the telemonitoring arm of
a trial have achieved improved outcomes compared with the
usual care available to people with COPD.10 12 For example,
telemonitoring in the context of an integrated care
service31—incorporating case management35 or providing
additional home visits36—reduced hospital admissions. Similarly,
in the recently published WSD trial, telemonitoring supported
by specialist community care, case management, or specific
arrangements with general practices according to local service
preferences was compared with usual care (that is, without the
specific services or arrangements developed to support the
telemonitoring).7 In this context, telemonitoring for participants
with diabetes, COPD, or heart failure was associated with lower
rates of emergency admissions, although the authors noted that
the difference was due to a short term increase in emergency
admissions in the control group.7 In our trial, the same clinical
service was available to participants in both groups (albeit
accessed considerably more frequently as a result of the
telemonitoring) and showed no difference in any outcomes. The
WSD trial with 3230 participants showed a significant reduction
in mortality,7 by contrast with Takahashi and colleagues, who
found a substantial increase in deaths.37Our trial, however, was
not powered for this outcome and our estimate of mortality is
thus imprecise and cannot contribute to the debate.
Our nested qualitative study suggested that patients were very
positive about the benefits of telemonitoring,16 27 29 but this was
not reflected by an improvement in respiratory-related quality
of life. Similarly, the lack of change in the HADS score
suggested that the intervention neither relieved nor exacerbated
overall levels of anxiety or depression. Our theoretical
framework for the telemonitoring intervention emphasised the
importance of empowering self management, improving
confidence of professionals by providing ongoing monitoring
data, and improving access to clinical services.15 Our nested
qualitative data suggested that continuity of care,29 facilitating
access to care,29 and supporting self management27 were all
perceived to be important facets of the intervention. However,
this did not translate into a difference in measured self efficacy
(a mediator of self management).
Our data did not allow us to distinguish telemonitoring alerts
triggered by clinically confirmed exacerbations requiring
treatment from false alarms that needed no additional
intervention. We observed a non-significant increase in the
number of self reported, treated exacerbations in the
telemonitoring group, although it is not clear whether this
finding was due to improved recognition of early exacerbations
or over treatment of “bad” days. Our results challenge previous
findings from a cohort study concluding that early recognition
and treatment improved exacerbation recovery, reduced risk of
admission, andwas associated with a better health related quality
of life.38 Despite frequent prompt responses to changes in
symptom scores, and a trend to increased treatment of
exacerbations, we found no benefit in any of these clinical
outcomes.
A key factor that could increase the number of false alerts and
limit the effectiveness of telemonitoring in COPD is the lack
of clear early predictors of an exacerbation.39 Physiological
parameters have not proved to be sufficiently predictive. This
is because they either change late in the course of the
exacerbation (for example, FEV1, oxygen saturation, heart rate,
temperature)39 or cannot be measured reliably (for example,
respiratory rate). Developing predictive algorithms with
clinically useful levels of sensitivity and specificity is thus a
priority for the future development of telemonitoring of COPD.
The substantial workload generated by the telemonitoring alerts
underlines the importance of piloting and assessing workforce
implications for both technological and clinical support services
during the planning and implementation phase of
reconfiguration. Crucial decisions about economies of scale and
the relative importance of continuity of care will be needed and
their effect monitored.29
Logistical issues with installation bedevilled the early months
of the intervention and will potentially have reduced any
effectiveness of our intervention. For telemonitoring to become
mainstream, the technology needs to adapt seamlessly to
variations in local connectivity as well as provide flexibility in
monitoring capability to meet individual clinical need. Use in
more specific contexts (such as to support early discharge until
the risk of readmission has receded40) could then be possible.
Conclusions and implications
Integration of telemonitoring into existing clinical
services—such that both intervention and control groups had
access to the same clinical care—had no effect on delaying time
to a hospital admission, and had a substantial impact on
workload. The positive effect of telemonitoring seen in previous
trials could thus be due to enhancement of the underpinning
clinical service rather than the telemonitoring communication.
Specific developments that could improve the performance of
telemonitoring in COPD in the future include the validation of
measures and algorithms that can predict potentially serious
exacerbations more reliably, and an understanding of clinical
contexts in which telemonitoring is most effective. In the
meantime, long term telemonitoring of people with COPD is
unlikely to reduce admissions unless it is a means of enhancing
clinical services.
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What is already known on this topic
Telemonitoring has attracted interest as a potential solution to the global challenge of providing care for ageing populations living with
long term conditions such as COPD
A Cochrane systematic review of telemonitoring in COPD reported a reduction in hospital admissions over 12 months, although
telemonitoring in these trials had been supported by enhanced clinical care which could reduce admissions in its own right
The specific role of telemonitoring in managing people with COPD, as opposed to the additional clinical services created to support it,
needs to be clarified
What this study adds
Integration of telemonitoring into existing clinical services—such that both intervention and control groups had access to the same clinical
care—did not delay time to a hospital admission, and had a substantial effect on workload
The positive effect of telemonitoring seen in previous trials could be due to enhancement of the underpinning clinical service rather than
the telemonitoring communication
Long term telemonitoring of people with COPD is unlikely to reduce admissions unless it is a lever for enhancing clinical services
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Tables
Table 1| Baseline characteristics of trial participants
Control (n=128)Telemonitoring (n=128)
68.4 (8.4)69.4 (8.8)Age in years (mean, SD)
65 (51)75 (59)Female sex (No of participants, %)
40.0 (17.0)44.0 (18.8)FEV1 % predicted (mean, SD)*
GOLD classification of severity of airflow limitation (No of participants)
4246Mild/moderate
4245Severe
4437Very severe
MRC dyspnoea score (No of participants, %)†
1 (1)4 (3)1 (least breathless)
26 (20)23 (18)2
27 (21)31 (24)3
31 (24)24 (19)4
43 (34)45 (35)5 (most breathless)
91 (71)78 (61)One or more comorbid conditions (No of participants, %)
2.5 (2.6)2.3 (2.1)No COPD admissions in previous year (mean, SD)‡
Smoking status (No of participants, %)
0 (0)2 (2)Never smoked
98 (77)89 (70)Ex-smoker
30 (23)37 (29)Current smoker
Scottish Index of Multiple Deprivation (No of participants, %)§
33 (26)39 (31)1 (most deprived)
37 (29)36 (28)2
17 (13)26 (20)3
20 (16)9 (7)4
21 (16)17 (13)5 (least deprived)
Questionnaires (mean, SD)
68.8 (15.2)68.6 (16.6)SGRQ
9.6 (4.6)9.8 (5.2)HADS (anxiety)
8.2 (4.1)8.9 (4.4)Depression
5.2 (2.3)5.0 (2.2)SECD6
23.8 (1.8)24.0 (2.1)MARS
7.8 (3.4)7.8 (3.3)LINQ
SD=standard deviation; GOLD=Global Initiative for Chronic Obstructive Lung Disease.
*Telemonitoring n=126, control n=128.
†Telemonitoring n=127, control n=128.
‡Telemonitoring n=127, control n=127.
§Telemonitoring n=127, control n=128.
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Table 2| Admissions and deaths per patient over one year
PAdjusted point estimate (95% CI)Control (n=128)Telemonitoring (n=128)*
Time to first hospital admission (days; median, IQR)
0.920.98 (0.66 to 1.44)†361 (113 to >365)362 (131 to >365)Admission with an exacerbation of COPD
0.460.87 (0.61 to 1.27)†287 (102 to >365)339 (131 to >365)Admission with an exacerbation of COPD or death
No of hospital admissions (mean, SD)
0.591.10 (0.78 to 1.56)1.1 (1.6)1.2 (1.9)Admission with a primary diagnosis of COPD exacerbation
0.431.14 (0.82 to 1.60)1.3 (1.8)1.5 (2.3)Admission in which COPD was the primary reason or a factor
in the admission
0.631.08 (0.80 to 1.45)2.0 (2.2)2.2 (2.9)All cause admissions
Duration of hospital admissions (days; mean, SD)
0.881.03 (0.71 to 1.50)8.8 (15.9)9.5 (19.1)Admission with a primary diagnosis of COPD exacerbation
0.851.04 (0.71 to 1.51)10.5 (18.5)11.9 (22.7)Admission in which COPD was the primary reason or a factor
in the admission
0.781.05 (0.75 to 1.48)14.0 (20.8)16.2 (27.2)All cause admissions
0.310.66 (0.29 to 1.48)‡21 (16)16 (13)Deaths (No, %)
IQR=interquartile range; SD=standard deviation.
*Reference group.
†Adjusted hazard ratio (95% confidence interval) for time to hospital admission.
‡Adjusted odds ratio (95% confidence interval) for number of deaths.
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Table 3| Questionnaire data
At 12 months after randomisation (mean, SD)At baseline (mean, SD)Questionnaire and trial group
SGRQ*
68.2 (16.3)67.2 (16.6)Telemonitoring (n=105)
67.3 (17.3)68.0 (16.0)Control (n=100)
HADS (anxiety)†
9.6 (5.0)9.8 (5.3)Telemonitoring (n=105)
9.1 (5.1)9.4 (4.7)Control (n=100)
HADS (depression)‡
9.1 (4.6)8.8 (4.3)Telemonitoring (n=105)
8.4 (4.2)8.3 (4.3)Control (n=100)
SECD6§
5.0 (2.2)5.1 (2.1)Telemonitoring (n=105)
5.3 (2.5)5.3 (2.2)Control (n=100)
LINQ¶
6.9 (3.1)7.9 (3.3)Telemonitoring (n=104)
6.8 (3.6)7.7 (3.5)Control (n=96)
MARS**
24.0 (1.7)24.0 (2.0)Telemonitoring (n=104)
23.7 (1.9)23.6 (1.9)Control (n=101)
Data include only participants who had complete information for each respective questionnaire at both time points. Non-completion at one year was due to death
(n=37), withdrawals from trial (n=4), and participants who declined to complete final questionnaires (n=10).
*Measures respiratory health related quality of life on a scale of 100 (greatest impairment) to 0.
†Assesses anxiety: scores ≤7 are normal, ≥11 indicate significant anxiety.
‡Assesses depression: scores ≤7 are normal: ≥11 indicate significant depression.
§Assesses confidence in ability to self manage symptoms on a scale of 1 (low self efficacy) to 10 (high self efficacy).
¶Measures information needs of people with COPD on a scale of 0 (low needs) to 25 (high needs).
**Assesses adherence to treatment on a scale of 0 (low adherence) to 5 (high adherence).
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Table 4| Logistics of installing telemonitoring equipment and training participants
No of days or participants
Time period (days; mean, SD)
56 (30)Time from randomisation to installation of broadband line and telemonitoring equipment
20 (21)Time from installation of equipment to completion of training
79 (48)Time from randomisation to commencing telemonitoring
Participants
128Participants randomised to telemonitoring
113Participants for whom equipment was successfully installed
—Reasons for non-installation of equipment: moved to nursing home, residential care, or staying with relatives (n=3); participant
declined (n=6; four participants were unhappy with equipment or installation process); died before equipment was installed (n=2);
participant was too ill when equipment was due to be installed (n=2); installation was unsuccessful or too expensive to install broadband
(n=2)
109Participants who received training
—Reasons for no training: participant declined training and equipment was withdrawn (n=2), participants was too ill when training was
scheduled (n=2), training was unsuccessful and equipment was withdrawn (n=1)
8Participants whose equipment was withdrawn
—Reasons for withdrawal: repeated malfunctioning of equipment (n=1); participant felt restricted by the home based equipment (n=1);
on advice of clinician because of inconsistent readings, increasing anxiety (n=3); additional health problemsmade use of telemonitoring
impossible or inappropriate (n=4)
SD=standard deviation.
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Table 5| Contacts with the telemonitoring services for patients under the care of the Edinburgh Community Respiratory Team andMidlothian
nurses
Control (n=92)Telemonitoring (n=97)
Contacts not related to alerts from telemonitoring
Total No of contacts
353510Telephone consultations
681821Home visits
—2Video link
66Other contacts
No of contacts per patient (mean, SD)
3.84 (5.73)5.26 (4.70)Telephone consultations
7.40 (7.72)8.46 (8.72)Home visits
—0.02 (0.14)Video link
0.07 (0.29)0.06 (0.24)Other contacts
Duration of contacts (minutes; mean, SD)
7.95 (9.71)6.70 (6.82)Telephone consultations
34.58 (16.13)33.69 (16.02)Home visits
—25.00 (7.07)Video link
45.00 (42.31)36.67 (41.55)Other contacts
Contacts in response to alerts from telemonitoring
Total number of contacts
—2326Telephone consultations
—113Home visits
—0Video link
—2Other contacts
No of contacts per patient (mean, SD)
—23.98 (22.34)Telephone consultations
—1.16 (2.02)Home visits
—0 (0)Video link
—0.02 (0.14)Other contacts
Duration of contacts (minutes; mean, SD)
—4.44 (3.84)Telephone consultations
—28.71 (16.99)Home visits
——Video link
—4.50 (0.71)Other contacts
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Figures
Fig 1 The Lothian COPD monitoring system.27 Reproduced with permission from reference 27
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Fig 2 Flow of participants through the trial. *Intention to treat analysis censored patients who died or withdrew before a
COPD admission
Fig 3 Kaplan-Meier curves showing time to first admission with an exacerbation of COPD
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Fig 4 Subgroup analyses on primary outcome
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